Dysfunction of proteasome and formation of lewy body in sporadic Parkinsons disease

Progress in Biochemistry and Biophysics

Volumn 35, Issue 5, 2008, Pages 502-511

  Li, Xing An ^a,b   Zhang, Ying Jiu ^b   Chang, Ming ^a   Wang, Dan Ping ^a   Liu, Tao ^b   Hu, Lin Sen ^a  

^a JUIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Aggregates; Aggresomes; Dysfunction of proteasomes; Lewy body; Loss of endoplasmic reticulum associated degradation (ERAD); Signal transduction; Sporadic Parkinson's disease (sPD)

Indexed keywords

EID: 48249088918     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. McNaught K S, Jackson T, JnoBaptiste R, et al. Proteasomal dysfunction in sporadic Parkinson' s disease. Neurology, 2006a, 66 (10 Suppl 4): S37-49
2. Spillantini M G, Crowther R A, Jakes R, et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson' s disease and dementia with lewy bodies. Proc Natl Acad Sci USA, 1998, 95 (11): 6469-6473
3. Lee H J, Lee S J. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem, 2002, 277 (50): 48976-48983
4. Dev K K, Hofele K, Barbieri S, et al. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 2003, 45(1): 14-44
5. Uversky V N, Gillespie J R, Fink A L. Why are "natively unfolded" proteins unstructured under physiologic conditions?. Proteins, 2000, 41(3): 415-427
6. Olanow C W, Perl D P, DeMartino G N, et al. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol, 2004, 3(8): 496-503
7. Garcia-Mata R, Gao Y S, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic, 2002, 3(6): 388-396
8. Shults C W. Lewy bodies. Proc Natl Acad Sci USA, 2006, 103(6): 1661-1668
9. McNaught K S, Olanow C W. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging, 2006b, 27(4): 530-545
10. Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke, 2004, 35(6): 1506-1518
11. McNaught K S, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol, 2003, 179: 38-45
12. Bulteau A L, Lundberg K C, Humphries K M, et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem, 2001, 276(32): 30057-30063
13. Hoozemans J J, van Haastert E S, Eikelenboom P, et al. Activation of the unfolded protein response in Parkinson' s disease. Biochem Biophys Res Commun, 2007, 354(3): 707-711
14. Chillaron J, Haas I G. Dissociation from BiP and retrotranslocation of unassembled immunoglobulin light chains are tightly coupled to proteasome activity. Mol Biol Cell, 2000, 11(1): 217-226
15. Johnston J A, Illing M E, Kopito R R. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton, 2002, 53(1): 26-38
16. Liu Y, Choudhury P, Cabrai C M, et al. Intracellular disposal of incompletely folded human alphal-antitrypsin involves release from camexin and post-translational trimming of asparagine-linked oligosaccharides. J Biol Chem, 1997, 272(12): 7946-7951
17. Qu D, Teckman J H, Omura S, et al. Degradation of a mutant secretory protein, alphal-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem, 1996, 271(37): 22791-22795
18. Mayer T U, Braun T, Jentsch S. Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein. EMBO J, 1998, 17(12): 3251-3257
19. Omura T, Kaneko M, Okuma Y, et al. A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin. J Neurochem, 2006, 99(6): 1456-1469
20. Glass A S, Huynh D P, Franck T, et al. Screening for mutations in synaptotagmin XI in Parkinson's disease. J Neural Transm Suppl, 2004, (68): 21-28
21. Hampe C, Ardila-Osorio H, Fournier M, et al. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet, 2006, 15(13): 2059-2075
22. Hiroi N, Zhu H, Lee M, et al. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proc Natl Acad Sci USA, 2005, 102 (52): 19132-19137
23. Taniguchi M, Taoka M, Itakura M, et al. Phosphorylation of adult type Sept5 (CDCrel-1) by cyclin-dependent kinase 5 inhibits interaction with syntaxin-1. J Biol Chem, 2007, 282(11): 7869-78676
24. Um J W, Min D S, Rhim H, et al. Parkin ubiquitinates and promotes the degradation of RanBP2. J Biol Chem, 2006, 281 (6): 3595-3603
25. Kopito R R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol, 2000b, 10(12): 524-530
26. Ferreon A C, Deniz A A. Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation. Biochemistry, 2007, 46(15): 4499-4509
27. Cappai R, Leek S L, Tew D J, et al A Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J, 2005, 19(10): 1377-1379
28. Speed M A, Wang D I, King J. Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nat Biotechnol, 1996, 14(10): 1283-1287
29. Lansbury PT Jr. Structural neurology: are seeds at the root of neuronal degeneration?. Neuron, 1997, 19(6): 1151-1154
30. Tsigelny I F, Bar-On P, Sharikov Y, et al. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J, 2007, 274(7): 1862-1877
31. Fink A L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des, 1998, 3(1): R9-23
32. Johnston J A, Ward C L, Kopito R R. Aggresomes: a cellular response to misfolded proteins. J Cell Biol, 1998, 143(7): 1883-1898
33. Kawaguchi Y, Kovacs J J, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 2003, 115(6): 727-738
34. Hook S S, Orian A, Cowley S M, et al. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci USA, 2002, 99 (21): 13425-13430
35. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 2005, 280(29): 26729-26734
36. Fabunmi R P, Wigley W C, Thomas P J, et al. Activity and regulation of the centrosome-associated proteasome. J Biol Chem, 2000, 275(1): 409-413
37. Trimmer P A, Borland M K, Keeney P M, et al. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem, 2004, 88(4): 800-812
38. Pletnikova O, West N, Lee M K, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging, 2005, 26(8): 1183-1192
39. Zhou Y, Gu G, Goodlett D R, et al. Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem, 2004, 279(37): 39155-39164
40. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport, 2001, 12(10): 2085-2090
41. Lennox G, Lowe J, Morrell K, et al. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry, 1989, 52(1): 67-71
42. Sasaki K, Doh-ura K, Wakisaka Y, et al. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathol (Berl), 2002, 104(3): 225-230
43. Hirabayashi M, Inoue K, Tanaka K, et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ, 2001, 8 (10): 977-984
44. Zhu J H, Guo F, Shelburne J, et al. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol, 2003, 13(4): 473-481
45. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol, 1997, 12(1): 25-31
46. Meriin A B, Sherman M Y. Department of biochemistry, boston university medical school, MA, USA. Role of molecular chaperones in neurodegenerative disorders. Int J Hyperthermia, 2005, 21 (5): 403-419
47. Ding Q, Dimayuga E, Martin S, et al. Characterization of chronic low-level proteasome inhibition on neural homeostasis. J Neurochem, 2003, 86(2): 489-497
48. Bence N F, Sampat R M, Kopito R R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 2001, 292 (5521): 1552-1555
49. Lee H J, Khoshaghideh F, Patel S, et al. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci, 2004, 24(8): 1888-1896
50. Katsuse O, Iseki E, Marui W, et al. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci, 2003, 211 (1-2): 29-35
51. Fortun J, Dunn WA Jr, Joy S, et al. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci, 2003, 23 (33): 10672-10680
52. Ishihara K, Nonaka A, Fukui T, et al. Lewy body-free nigral degeneration-a case report. J Neurol Sci, 2002, 198(1-2): 97-100
53. Wakabayashi K, Toyoshima Y, Awamori K, et al. Restricted occurrence of Lewy bodies in the dorsal vagal nucleus in a patient with late-onset parkinsonism. J Neurol Sci, 1999, 165(2): 188-191
54. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci, 2003, 26:81-104
55. Tompkins M M, Hill W D. Contribution of somal Lewy bodies to neuronal death. Brain Res, 1997a, 775(1-2): 24-29
56. Tompkins M M, Basgall E J, Zamrini E, et al. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol, 1997, 150(1): 119-131
57. Lee D H, Goldberg A L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol, 1998, 8(10): 397-403
58. Petrucelli L, O'Farrell C, Lockhart P J, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron, 2002, 36(6): 1007-1019
59. Rideout H J, Lang-Rollin I C, Savalle M, et al. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem, 2005, 93(5): 1304-1313
60. Lee M, Hyun D H, Marshall K A, et al. Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Free Radic Biol Med, 2001, 31(12): 1550-1559
61. Noda K, Kitami T, Gai W P, et al. Phosphorylated IkappaBalpha is a component of Lewy body of Parkinson's disease. Biochem Biophys Res Commun, 2005, 331(1): 309-317
62. Rideout H J, Larsen K E, Sulzer D, et al. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem, 2001, 78(4): 899-908
63. Park S S, Lee D. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures. Eur J Neurosci, 2006, 23(11): 2908-2914
64. Lim K L, Dawson V L, Dawson T M. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson' s and other conformational diseases?. Neurobiol Aging, 2006, 27(4): 524-529
65. Chung K K, Zhang Y, Lim K L, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med, 2001, 7(10): 1144-1150
66. Ihara M, Tomimoto H, Kitayama H, et al. Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem, 2003, 278(26): 24095-24102
67. Miwa H, Kubo T, Suzuki A, et al. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci Lett, 2005, 380(1-2): 93-98
68. Kahle P J, Neumann M, Ozmen L, et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol, 2001, 159(6): 2215-2222
69. Jin J, Meredith G E, Chen L, et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res Mol Brain Res, 2005, 134(1): 119-138